IP Library Granted Patent US 8,846,657
Granted Patent B2
US 8,846,657 · App. 14/132,946 · Granted Sep 30, 2014

Substituted imidazopyridines as HDM2 inhibitors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,846,657
App. No.
14/132,946
Granted
Sep 30, 2014
Kind
B2
Abstract

The present invention provides substituted imidazopyridines as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.

Claims (49)

1. A compound selected from the group consisting of:

or a stereoisomer thereof;

or a pharmaceutically acceptable salt thereof;

or a pharmaceutically acceptable salt of the stereoisomer thereof.

2. A compound selected from the group consisting of:

or a stereoisomer thereof;

or a pharmaceutically acceptable salt thereof;

or a pharmaceutically acceptable salt of the stereoisomer thereof.

3. A pharmaceutical composition comprising a compound of claim 1 , in combination with at least one pharmaceutically acceptable carrier.

4. A pharmaceutical composition comprising a compound of claim 2 , in combination with at least one pharmaceutically acceptable carrier.

5. The compound of claim 1 that is

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 that is

or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1 that is

or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1 that is

or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1 that is

or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1 that is

or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1 that is

or a pharmaceutically acceptable salt thereof.

12. The compound of claim 1 that is

or a pharmaceutically acceptable salt thereof.

13. The compound of claim 1 that is

or a pharmaceutically acceptable salt thereof.

14. The compound of claim 1 that is

or a pharmaceutically acceptable salt thereof.

15. The compound of claim 2 that is

or a pharmaceutically acceptable salt thereof.

16. The compound of claim 2 that is

or a pharmaceutically acceptable salt thereof.

17. The compound of claim 2 that is

or a pharmaceutically acceptable salt thereof.

18. A pharmaceutical composition comprising a compound of claim 5 , in combination with at least one pharmaceutically acceptable carrier.

19. A pharmaceutical composition comprising a compound of claim 6 , in combination with at least one pharmaceutically acceptable carrier.

20. A pharmaceutical composition comprising a compound of claim 7 , in combination with at least one pharmaceutically acceptable carrier.

21. A pharmaceutical composition comprising a compound of claim 8 , in combination with at least one pharmaceutically acceptable carrier.

22. A pharmaceutical composition comprising a compound of claim 9 , in combination with at least one pharmaceutically acceptable carrier.

23. A pharmaceutical composition comprising a compound of claim 10 , in combination with at least one pharmaceutically acceptable carrier.

24. A pharmaceutical composition comprising a compound of claim 11 , in combination with at least one pharmaceutically acceptable carrier.

25. A pharmaceutical composition comprising a compound of claim 12 , in combination with at least one pharmaceutically acceptable carrier.

26. A pharmaceutical composition comprising a compound of claim 13 , in combination with at least one pharmaceutically acceptable carrier.

27. A pharmaceutical composition comprising a compound of claim 14 , in combination with at least one pharmaceutically acceptable carrier.

28. A pharmaceutical composition comprising a compound of claim 15 , in combination with at least one pharmaceutically acceptable carrier.

29. A pharmaceutical composition comprising a compound of claim 16 , in combination with at least one pharmaceutically acceptable carrier.

30. A pharmaceutical composition comprising a compound of claim 17 , in combination with at least one pharmaceutically acceptable carrier.

Assignments (4)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2013
From: CHRISTOPHER, MATTHEW P.; FRADERA LLINAS, FRANCESC XAVIER; MACHACEK, MICHELLE; MARTINEZ, MICHELLE; REUTERSHAN, MICHAEL HALE; SHIZUKA, MANAMI; SUN, BINYUAN; THOMPSON, CHRISTOPHER FRANCIS; TROTTER, B. WESLEY; ALTMAN, MICHAEL D.; BOGEN, STEPHANE L.; DOLL, RONALD J.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 031827/0664 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2013
From: VOSS, MATTHEW E.
To: ALBANY MOLECULAR RESEARCH, INC.
Reel/Frame 031828/0792 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2013
From: ALBANY MOLECULAR RESEARCH, INC.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 031829/0186 →